| Fujikawa et al. (2013) [33] | Serelis et al. (2015) [34] | Hamanoue et al. (2015) [18] | Yilmaz et al. (2015) [19] | Umeda et al. (2015) [35] | Our cases |
---|---|---|---|---|---|---|
Total number of patients | 1 | 1 | 1 | 11 | 1 | 12 |
Adult/children | 1/0 | 1/0 | 1/0 | 11/0 | 1/0 | 12/0 |
Duration of Tocilizumab treatment, mean (months) | Not specified | 48 | 41 | 57 | 9 | 18 |
Gene analysis | ||||||
 M694V/M694V |  |  |  | 7 |  | 4 |
 M694V/M680I |  |  |  | 2 |  | 1 |
 M694I/- heterozygous | 1 |  |  |  |  |  |
 Other |  | Not specified | 1 | 2 | 1 | 7 |
Indications for Tocilizumab treatment | ||||||
 Amyloidosis |  | 1 | 1 | 11 |  | 12 |
 Frequent attacks (fever, serositis) | 1 | 1 | 1 |  | 1 |  |
 Arthritis/spondylitis |  | 1 | 1 |  |  |  |
 Protracted myalgia |  |  |  |  | 1 |  |
 Henoch-Schonlein purpura |  |  |  |  |  |  |
 Colchicine intolerance/side effect |  |  |  |  |  |  |
Effect of Tocilizumab during follow up | ||||||
 No attacks | 1 |  | Unknown | 8 | 1 | 10 |
 Decrease number of attacks |  | 1 |  |  |  | 1 |
 No response |  |  |  |  |  | 1 |
 Proteinuria in patients with amyloidosis |  | decreased | decreased | Decreased in 7 |  | 9 |
Side effects | None | Unknown | Unknown | Elevation of liver enzymes, mild thrombocytopenia | Not specified | Transient diplopia, deterioration in hypertension |